FDA Clears Varian’s Proton Therapy System

January 17, 2014 — The U.S. Food and Drug Administration cleared Varian Medical Systems’ updated ProBeam proton therapy system.

 

Varian's ProBeam system gives clinicians options for delivering dose precisely to minimize dose to healthy tissue in the course of delivering proton therapy treatments for cancer. Its scanning beam technology enables intensity-modulated proton therapy (IMPT) by modulating dose levels on a spot-by-spot basis throughout the treatment area. Irradiations from multiple angles are efficiently combined to improve control of dose distributions. Scanning beam technology also eliminates the need to manually insert separate shaping accessories for each beam angle in order to match the beam to the shape of the tumor.

 

Varian's scanning beam IMPT technology is already in use at the Rinecker Proton Therapy Center, Munich, Germany, and has treated more than 1,500 patients at the site. Varian also has contracts to install ProBeam systems at four sites in the United States, one in Saudi Arabia and one in Russia.

 

For more information: www.varian.com